Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis
| Autor: | Jean-Philippe Lacour, Irina Turchin, Marie Holst Mørch, Lyn Guenther, Terri Nutt, Adam Reich, Anna Szponar-Bojda, Stephen K. Tyring, William Philip Werschler, Zygmunt Adamski, Neil S. Sadick, Agnieszka Miasik-Pogodzinska, Charles Lynde, Monika Liljedahl, Kim A. Papp |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Betamethasone dipropionate Subgroup analysis Dermatology Administration Cutaneous Gastroenterology Betamethasone chemistry.chemical_compound Calcitriol Adrenal Cortex Hormones Recurrence Internal medicine Psoriasis Medicine Humans Adverse effect Calcipotriol Body surface area Aerosols business.industry Hazard ratio medicine.disease Drug Combinations Treatment Outcome chemistry Corticosteroid lipids (amino acids peptides and proteins) Dermatologic Agents business medicine.drug |
| Zdroj: | The Journal of dermatological treatment. 33(4) |
| ISSN: | 1471-1753 |
| Popis: | OBJECTIVE In PSO-LONG, long-term proactive management (PAM) of psoriasis with fixed-dose combination calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g (Cal/BD) aerosol foam was superior to conventional reactive management. This post-hoc analysis investigated long-term PAM with Cal/BD foam in PSO-LONG patients who could be more susceptible to corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression. METHODS Efficacy and safety of PAM with Cal/BD foam (twice-weekly) versus reactive management (twice-weekly vehicle foam), with once-daily rescue Cal/BD foam for four weeks following relapse, was assessed in the HPA subgroup (n = 66); patients had moderate-to-severe psoriasis (physician global assessment score ≥3; 10-30% body surface area affected). Primary endpoint was time to first relapse. RESULTS PAM with Cal/BD foam was associated with longer median time to first relapse (111 versus 31 days), reduced risk of first relapse (hazard ratio: 0.49; p = .029), greater proportion of days in remission (17%; p = .001) and reduced rate of relapse (60% reduction; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|